HC Wainwright Has Optimistic Outlook of SLNO Q1 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – HC Wainwright upped their Q1 2025 earnings estimates for Soleno Therapeutics in a note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.80) per share for the quarter, up from their prior forecast of ($0.83). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $1.06 EPS and FY2026 earnings at $1.39 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

Other equities research analysts also recently issued research reports about the stock. Guggenheim restated a “buy” rating and issued a $81.00 target price (up previously from $70.00) on shares of Soleno Therapeutics in a research note on Friday, March 28th. Stifel Nicolaus boosted their price target on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, March 28th. Laidlaw upped their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. Robert W. Baird lifted their target price on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, March 27th. Finally, UBS Group set a $105.00 price target on Soleno Therapeutics in a research report on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $99.63.

Soleno Therapeutics Price Performance

Shares of NASDAQ:SLNO opened at $67.48 on Thursday. The business’s fifty day moving average price is $51.19 and its two-hundred day moving average price is $50.75. Soleno Therapeutics has a fifty-two week low of $36.61 and a fifty-two week high of $74.00. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -20.33 and a beta of -2.29.

Institutional Investors Weigh In On Soleno Therapeutics

Several institutional investors have recently modified their holdings of SLNO. AlphaQuest LLC lifted its holdings in Soleno Therapeutics by 1,154.4% in the fourth quarter. AlphaQuest LLC now owns 715 shares of the company’s stock valued at $32,000 after buying an additional 658 shares during the period. US Bancorp DE acquired a new position in shares of Soleno Therapeutics in the 4th quarter valued at $34,000. Avanza Fonder AB bought a new position in shares of Soleno Therapeutics in the 4th quarter worth $76,000. Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Soleno Therapeutics in the 4th quarter worth $81,000. Finally, Avior Wealth Management LLC bought a new stake in Soleno Therapeutics in the fourth quarter valued at about $89,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Insiders Place Their Bets

In other Soleno Therapeutics news, insider Patricia C. Hirano sold 128,653 shares of the stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total value of $8,789,572.96. Following the transaction, the insider now directly owns 55,789 shares in the company, valued at approximately $3,811,504.48. This trade represents a 69.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of the business’s stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the sale, the chief executive officer now owns 577,076 shares of the company’s stock, valued at approximately $39,021,879.12. The trade was a 54.78 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 942,672 shares of company stock valued at $64,058,781. Insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.